000 02108nam a2200373Ia 4500
001 ocm52167551
003 OCoLC
005 20180312141842.0
007 he bmb024bbca
008 030502s2002 dcua bb f000 0 eng d
040 _aFPS
_beng
_cFPS
_dOCLCQ
_dFCMBL
_dOCLCQ
_dOCLCO
_dOCLCQ
_dGPO
_dMvI
043 _an-us---
074 _a1019-B-01 (MF)
088 _aSerial no. 107-142 (United States. Congress. House. Committee on Energy and Commerce)
086 0 _aY 4.C 73/8:107-142
099 _aY 4.C 73/8:107-142
110 1 _aUnited States.
_bCongress.
_bHouse.
_bCommittee on Energy and Commerce.
_bSubcommittee on Oversight and Investigations.
245 1 3 _aAn inquiry into the ImClone cancer-drug story :
_bhearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, June 13 and October 10, 2002.
260 _aWashington :
_bU.S. G.P.O. :
_bFor sale by the Supt. of Docs., U.S. G.P.O. [Congressional Sales Office],
_c2002.
300 _aiii, 759 pages :
_billustrations ;
_c24 cm
336 _atext
_btxt
_2rdacontent
337 _amicroform
_bh
_2rdamedia
338 _amicrofiche
_bhe
_2rdacarrier
504 _aIncludes bibliographical references.
500 _a"Serial no. 107-142."
500 _aShipping list no.: 2003-0183-M.
500 _aCRDP Program record.
533 _aMicrofiche.
_bWashington :
_cSupt. of Docs., U.S. G.P.O.,
_d2003.
_e9 microfiches : negative.
610 2 0 _aImClone Systems Incorporated
_xCorrupt practices.
650 0 _aCetuximab
_xTesting.
650 0 _aDrugs
_zUnited States
_xTesting.
650 0 _aInsider trading in securities
_zUnited States.
776 0 8 _iOnline version:
_aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.
_tInquiry into the ImClone cancer-drug story
_w(OCoLC)852784181
776 0 8 _iPrint version:
_aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.
_tInquiry into the ImClone cancer-drug story
_w(DLC) 2003426647
_w(OCoLC)51586262
999 _c269571
_d269571